Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ponsegromab in Healthy Japanese Adults
NCT03974776Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2019
- Primary completion
- Jan 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cancer cachexia comparing Ponsegromab with Placebo (2 arms). Primary endpoint: Incidence of participants experiencing Adverse Events (AE). Started Jul 2019; status: completed.
02
Drugs
ponsegromab
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT03974776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974776.